SET/TAF-I anticorps (AA 147-235) (HRP)

N° du produit ABIN7166109

Détail du produit anti-SET/TAF-I anticorps (HRP)

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Épitope: AA 147-235

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SET/TAF-I est conjugé à/à la HRP

Application: ELISA

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Protein SET protein (147-235AA)

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur SET/TAF-I

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Autre désignation: SET (SET Produits)

Synonymes: anticorps 2PP2A, anticorps I2PP2A, anticorps IGAAD, anticorps IPP2A2, anticorps PHAPII, anticorps TAF-I, anticorps TAF-IBETA, anticorps 2610030F17Rik, anticorps 5730420M11Rik, anticorps AA407739, anticorps I-2PP2A, anticorps StF-IT-1, anticorps 2pp2a, anticorps i2pp2a, anticorps igaad, anticorps ipp2a2, anticorps phapii, anticorps set, anticorps set-a, anticorps set-b, anticorps taf-ibeta, anticorps wu:fb30g11, anticorps wu:fd16c08, anticorps SET nuclear proto-oncogene, anticorps SET nuclear oncogene, anticorps SET translocation, anticorps SET nuclear proto-oncogene L homeolog, anticorps SET nuclear proto-oncogene b, anticorps SET, anticorps Set, anticorps LOC403555, anticorps set.L, anticorps setb

Sujet:

Background: Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher.

Aliases: 2PP2A antibody, HLA DR associated protein II antibody, HLA-DR-associated protein II antibody, I 2PP2A antibody, I-2PP2A antibody, I2PP2A antibody, IGAAD antibody, Inhibitor of granzyme A activated DNase antibody, Inhibitor of granzyme A-activated DNase antibody, Inhibitor of GzmA-activated DNase antibody, inhibitor-2 of protein phosphatase-2A antibody, IPP2A2 antibody, PHAPII antibody, Phosphatase 2A inhibitor I2PP2A antibody, protein phosphatase type 2A inhibitor antibody, Protein SET antibody, Set antibody, SET nuclear oncogene antibody, SET translocation antibody, SET translocation (myeloid leukemia-associated) antibody, SET_HUMAN antibody, TAF I antibody, TAF IBETA antibody, TAF-I antibody, TAFI antibody, Template activating factor I antibody, Template-activating factor I antibody, Template-Activating Factor-I, chromatin remodelling factor antibody

UniProt: Q01105

Pathways: Apoptose